Type 2 Diabetes – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US)
Metformin remains the most heavily prescribed type 2 diabetes (T2D) drug and dominates the early lines of therapy before disease progression requires insulin replacement. More effective, safer, and better tolerated therapies, such as sodium-glucose cotransporter-2 (SGLT-2) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, and GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) agonists, are reshaping the current T2D treatment landscape. This report covers key current therapies for newly diagnosed and recently treated T2D patients, including a broad range of agents (over 60 drugs) from both established and recently launched classes that are now jostling for position in the treatment paradigm.
Questions answered
- What patient shares do key therapies garner by line of therapy in newly diagnosed T2D patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed T2D patients?
- How has tirzepatide been integrated into the treatment algorithm, and what is its source of business?
- What percentage of T2D patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of T2D patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
Geography: United States
Real-world data: Patient-level claims data analysis
Key drugs: Dapagliflozin, empagliflozin, insulin aspart, insulin glargine (U100), metformin, semaglutide (SC), tirzepatide
Key analyses: Brand / therapy usage across patient sample; Newly diagnosed patient analysis; Treatment initiation and progression; Line of therapy analysis; Combination therapy analysis; Source of business for recently treated patients; Persistency and compliance analysis; Product-level patient flow
Key feature: Dashboard featuring interactive visuals, easy navigation, and expanded analyses
Product description
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:
- Understand patient flow between lines of therapy.
- Evaluate your brand share against competitors.
- Accurately assess your source of business.
- Quantify opportunities at different stages of the treatment algorithm.
Product enhancement
Treatment Algorithms: Claims Data Analysis leverages Clarivate’s proprietary Real-World Data, which brings larger patient samples, broader payer coverage, and faster availability for more robust and timely analyses. Additionally, we include new patient demographic analyses: age, gender, ethnicity, and region.
